• D-Luciferin Workflows for Glioblastoma BLI

  2026-08-22

  D-Luciferin enables sensitive firefly luciferase readouts for longitudinal tumor burden assessment, promoter activity, and intracellular ATP quantification. This workflow translates a targeted glioblastoma siRNA study into practical reporter-assay choices while separating delivery, viability, and true biological response.

• NMDA Receptor Activation: From Excitotoxicity to Ferroptosis

  2026-08-21

  NMDA (N-Methyl-D-aspartic acid) is more than an excitotoxicity tool: it can be used to connect receptor-driven calcium loading with oxidative injury and ferroptosis-associated phenotypes. This article translates a recent glaucoma study into practical assay-design decisions for reproducible neuroscience research.

• Ridaforolimus at the mTOR–Senescence Frontier

  2026-08-20

  Ridaforolimus (Deforolimus, MK-8669) provides a precise way to interrogate mTOR-dependent growth, angiogenesis, and cell-fate decisions. This thought-leadership article connects its oncology research profile with machine-learning-enabled senolytic discovery and translates the biology into practical, reproducible workflows.

• Degarelix Acetate: Evidence for Rapid Androgen Deprivation

  2026-08-20

  Klotz’s 2009 review examined degarelix acetate as a third-generation GnRH receptor antagonist designed to suppress testosterone without the initial surge associated with GnRH agonists. Its synthesis of phase II and III evidence highlights faster endocrine control, earlier prostate-specific antigen responses, and a tolerability profile relevant to prostate cancer research and cancer hormone therapy.

• Ceapin-A7 Workflows for ATF6α ER Stress Studies

  2026-08-19

  Use Ceapin-A7 as a branch-selective chemical probe to separate ATF6α signaling from broader unfolded protein response effects. This practical workflow connects endoplasmic reticulum stress research with osteogenic injury models while clearly distinguishing established evidence from testable hypotheses.

• REV1–DHX36 Control of G-Quadruplex Replication

  2026-08-19

  A 2026 Nucleic Acids Research study identifies a direct REV1–DHX36 interaction that coordinates G-quadruplex unwinding, replication-fork progression, and suppression of single-stranded DNA gaps. The findings position REV1 as more than a translesion polymerase scaffold and provide a mechanistic framework for understanding how G4 stabilization amplifies replication stress and DNA damage response signaling.

• Tiamulin: From MIC to Veterinary PK/PD

  2026-08-18

  Tiamulin (Thiamutilin) is examined through a practical MIC-to-PK/PD framework for veterinary infectious-disease research. This article connects ribosomal mechanism, exposure targets, assay design, and anti-inflammatory interpretation without overstating translational evidence.

• BMP4–GPX4 Protects RGCs in NMDA Glaucoma

  2026-08-18

  The reference study identifies a BMP4–GPX4 axis that connects ferroptosis control with retinal stem cell performance in an NMDA-induced mouse model of glaucoma-related retinal ganglion cell injury. Its findings support integrated measurement of oxidative stress, iron handling, pathway activation, and stem cell differentiation when evaluating regenerative strategies.

• N1-Methylpseudo-UTP for Stable RNA Workflows

  2026-08-17

  N1-Methylpseudo-UTP enables a controlled route to more stable, translation-ready RNA for mechanistic assays, reporter studies, and mRNA vaccine development. This practical guide connects modified-nucleotide IVT with the assay design lessons of a recent R2 retrotransposon insertion study without overstating what that DNA-integration work proves about modified RNA.

• ARCA EGFP mRNA (5-moUTP): Translational Control

  2026-08-17

  A thought-leadership analysis of how cap orientation, modified nucleotides, poly(A) architecture, and formulation discipline shape the reliability of fluorescent mRNA reporters. The article translates molecular design into practical guidance for assay development, storage evaluation, and translational decision-making.

• Click-Compatible BmTyr for T-Cell Proteome Mapping

  2026-08-16

  The reference study introduces an engineered BmTyr tyrosinase platform that enables biotin-free proximity labeling in primary T cells through alkyne-phenol chemistry and post-labeling click conjugation. Its modular detection strategy supports fluorescence imaging, affinity enrichment, mass spectrometry, and antibody-independent validation, while revealing chromatin-associated localization of NKAP in the TNFα signaling context.

• Therapy Sequencing in Waldenström Macroglobulinemia

  2026-08-15

  The 2021 reference paper reframes Waldenström macroglobulinemia treatment selection as a genomically informed sequencing problem, emphasizing the clinical relevance of MYD88 and CXCR4 status. Its practical contribution is a patient-centered framework that integrates genotype, disease presentation, comorbidities, toxicity, and emerging targeted therapies rather than treating one regimen as universally preferred.

• Ionophore Toxicity in Animals: Molecular and Clinical Review

  2026-08-14

  The reference review connects clinical ionophore poisoning in animals with membrane ion transport, mitochondrial dysfunction, and damage to cardiac and skeletal muscle. Its main practical contribution is an integrated framework for interpreting species-, age-, dose-, and drug-interaction effects, including the clinically important relationship between ionophores and Tiamulin.

• Rhodamine B Workflows for Nanomedicine Imaging

  2026-08-14

  Rhodamine B combines practical solvent flexibility with strong utility as a cell-labeling fluorescent dye, making it useful for tracking nanoparticle uptake, tissue distribution, and fluorescence-based assay performance. This workflow-focused guide shows how to adapt Basic Violet 10 for imaging studies inspired by trypsin-responsive pancreatitis nanomedicine while separating validated findings from assay-development recommendations.

• Triple-Target Inhibition in BRAFV600E Melanoma

  2026-08-13

  This study shows that eIF4F inhibition alone can trigger compensatory ERK1/2, AKT1, and EZH2 signaling in BRAFV600E melanoma cells. Combining an eIF4F inhibitor with AKT1 and EZH2 blockade enhanced apoptosis, reduced proliferation, and restored sensitivity to eIF4F and BRAF inhibition in cellular and in vivo models.

14866 records 1/992 page Next 12345 下5页 Last page